13 -3 (41) 2022 — Khaydarova F.A., Inogamova D.T. — THE ROLE OF BIOMARKERS IN PREDICTING OF HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITIS

THE ROLE OF BIOMARKERS IN PREDICTING OF HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITIS

Khaydarova F.A., Republican Specialized Scientific and Practical Medical Center of Endocrinology of Public Health Ministry of the RUz named by Acad. Yo. Kh. Turakulov, the department of neurosurgery, Republic of Uzbekistan, 100125, Tashkent,  Mirzo Ulugbek str. 56.

Inogamova D.T. Republican Specialized Scientific and Practical Medical Center of Endocrinology of Public Health Ministry of the RUz named by Acad. Yo. Kh. Turakulov, the department of neurosurgery, Republic of Uzbekistan, 100125, Tashkent,  Mirzo Ulugbek str. 56.

Resume

In this article, the authors performed a review of literature on the value of biomarkers in predicting complications after endovascular revascularization in patients with diabetes mellitus type 2. The authors concluded that the future use of biomarkers with heart failure  stay on the multimarcere panel strategy, which will include a specific combination of biomarkers (galectin 3, growth differentiation factor-15, GDF-15), renal dysfunction (lipocalin associated with neutrophil gelatinase, NGAL; kidney damage molecule-1, KIM-1), neurohumoral activation (adrenellin, MR-PROADM; Coppentine) and oxidative stress (Ceruloplasmin; Myeloperoxidase, MPO; 8-hydroxy-2′-deoxyiguanosine, 8-OHDG; Tyoracedoxin 1, TRX1)  in patients with heart failure.

Key words: diabetes mellitus 2 type, ischemic heart disease, markers

First page

75

Last page

81

For citation: Khaydarova F.A., Inogamova D.T. THE ROLE OF BIOMARKERS IN PREDICTING OF HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITIS //New Day in Medicine 3(41)2022 75-81 https://clck.ru/eotDu

LIST OF REFERENCES:

1. Braunwald E., Grossman W. Clinical aspects of heart failure. In: Braunwald E., editor. Heart Disease: A Textbook of Cardiovascular Medicine. Saunders; Philadelphia: 1992. pp. 444–463. 
2. Yancy C., Jessup M., Bozkurt B., Butler J., Casey D., Jr, Drazner M. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:147–239. 
3. Ambrosy A.P., Fonarow G.C., Butler J. The global health and economic burden of hospitalizations for heart FailureLessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(April (12)):1123–1133.
4. Census of India Website: Office of the Registrar General and Census Commissioner, India. Censusindia.gov.in.
5. Huffman M.D., Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India. 2010;23(October (5)):283–288
6. Vivek Chaturvedi et al. HEART FAILURE IN INDIA: The INDUS (INDia Ukieri Study) Study. JPCS. 2016, 2016.
7. Benjamin E.J., Blaha M.J., Chiuve S.E. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(March (10)):e146–603
8. Mozaffarian D., Benjamin E.J., Go A.S. Heart disease and stroke statistics—2015 update a report from the American Heart Association. Circulation. 2015;131(January (4)):e29–322.
9. Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with Stable heart failure and healthy adults. Clin Chem. 2016;62:360–366. doi: 10.1373/clinchem.2015.246553. 
10. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol. 2015;182:168–170. doi: 10.1016/j.ijcard.2014.12.137.
11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200
12. de Boer RA, Daniels LB, Maisel AS, Januzzi JL., Jr State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–569. [PubMed] [Google Scholar]
13. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168:2186–2194. [PubMed] [Google Scholar]
14. Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer longterm therapy guidance. J Card Fail. 2013;19:821–828. [PubMed] [Google Scholar]
15. Bayes-Genis A, Zamora E, de Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail. 2013;19:768–775. [PubMed] [Google Scholar]
16. Kim MS, Jeong TD, Han SB, Min WK, Kim JJ. Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J Korean Med Sci. 2015;30:569–575. [PMC free article] [PubMed] [Google Scholar]
17. Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14:75–92. [PubMed] [Google Scholar]
18. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148–2159. [PubMed] [Google Scholar]
19. Jackson CE, Haig C, Welsh P, et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail. 2016;18:1491–1498.
20. Chun-Chieh Wang,¹ Cho-Kai Wu,² Ming-Lung Tsai,¹ Chii-Ming Lee 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart FailureActa Cardiol Sin. 2019 May; 35(3): 244–283.doi: 10.6515/ACS.201905_35(3).20190422A